贝伐单抗一线治疗结直肠癌进展后二线应用的临床生存获益:来自于BRiTE的研究

Clinical Overall Survival Benefit of Bevacizumab beyond First Progression in Colorectal Cancer:From BRiTE Study

导出

摘要 1 文献来源 Grothey A, Sugrue MM, Purdre DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer： Results from a large observational cohort study（BRiTE） [J]. J Clin Oncol, 2005,26 （33）： 5326-5334.

作者何友兼董秋美

机构地区中山大学肿瘤防治中心内科广东省人民医院肿瘤中心

出处《循证医学》 CSCD 2009年第3期150-151,共2页 The Journal of Evidence-Based Medicine

关键词结直肠肿瘤贝伐单抗总生存期 colorectal neoplasms Bevacizumab overall survival

分类号 R735.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献3

1Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for matestatic colorectal cancer[J].N Engl J Med,2004,350(23):2335-2342.
2Kabbinavar FF,Hambleton J,Mass RD,et al.Combined analysis of efficacy:The addition of Bevacizumab to Fluorluracil/ Leucovorin improves survival for patients with matasiatic colorectal cancer[J].J Clin Oncol,2005,23(16):3706-3712.
3Giantonio BJ,Catalano PJ,Meropol NJ,et al.Bevacizumab in combination with Oxaliplatin,Fluorouracil,and Leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:Results from the Eastern Cooperative Oncology Group Study E3200[J].J Clin Oncol,2007,25(12):1539-1544.

1Feng Li,Benjamin Tiede,Joan Massague,Yibin Kang.Beyond tumorigenesis: cancer stem cells in metastasis[J].Cell Research,2007,17(1):3-14. 被引量：86
2邱继刚.Clinical values of detecting excision repair cross complementing 1 and top-oisomerase I in individualized therapies of metastatic colorectal cancer[J].China Medical Abstracts(Internal Medicine),2014,31(1):38-38.
3李剑英,王建红,许春明,杨磊,季从飞,谭清和.西妥昔单抗联合FOLFIRI方案一线治疗转移性结直肠癌的疗效观察[J].临床与病理杂志,2014,34(4):420-424. 被引量：3
4张晓瑞.西妥昔单抗联合化疗治疗转移性结直肠癌疗效观察[J].山西职工医学院学报,2016,26(5):30-32. 被引量：1
5Bing-QuanWu,TaoWang,KunChen,Ji-YaoWang,Jie-PingZhang,San-RenLi.Helicobacterpylori infection and gastric cancer:evidence from a retrospective cohort study and nested case-control study in China[J].World Journal of Gastroenterology,2002,8(6):1103-1107. 被引量：8
6Zacharenia Saridaki,Vassilis Georgoulias,John Souglakos.Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer[J].World Journal of Gastroenterology,2010,16(10):1177-1187. 被引量：3
7李慧明,余英豪.转移性结直肠癌靶向治疗中的关键分子[J].世界华人消化杂志,2014,22(3):350-358. 被引量：6
8曲颜丽,赛福丁·克尤木,唐勇.贝伐珠单抗联合化疗治疗转移性结直肠癌的疗效和安全性[J].世界华人消化杂志,2016,24(17):2748-2754. 被引量：2
9陈青青,范惠珍.Tiam 1与转移性结直肠癌的研究进展[J].宜春学院学报,2016,38(9):17-20.
10杨宇飞,葛建忠,吴煜,许云,梁碧颜,雒琳,关显文,刘端祺,张侠,宋飞翔,耿振英.Cohort Study on the Effect of a Combined Treatment of Traditional Chinese Medicine and Western Medicine on the Relapse and Metastasis of 222 Patients with Stage Ⅱ and Ⅲ Colorectal Cancer after Radical Operation[J].Chinese Journal of Integrative Medicine,2008,14(4):251-256. 被引量：28

循证医学

2009年第3期

浏览历史

内容加载中请稍等...

贝伐单抗一线治疗结直肠癌进展后二线应用的临床生存获益:来自于BRiTE的研究

参考文献3

相关作者

相关机构

相关主题

浏览历史